Une étude de LY3295668 Erbumine chez des participants avec neuroblastome en rechute/réfractaire

To join this study, children and young people need to be between 2 and 21 years old and have neuroblastoma that has come back or hasn't responded to earlier treatments. The disease must be active in areas like their bones, bone marrow, or soft tissues. Participants also need to be able to swallow capsules, as the study medicine is taken this way.

There are also some reasons why someone might not be able to join. For example, if they've had certain types of transplants (like a stem cell or organ transplant), or if the neuroblastoma has spread to their brain or spinal cord without being treated. They also shouldn't have other serious illnesses, problems absorbing medicines, or a known allergy to any part of the study treatment. If they've taken similar medicines recently or have certain active infections like HIV or hepatitis, this would also mean they can't take part.

If you decide to take part in this study, you will be given the study medicine, LY3295668 erbumine, which you will take as capsules. You will need to attend regular appointments at the hospital. At these visits, doctors will perform examinations and tests, which might include blood tests and scans, to check on your health and how you are responding to the medicine. They will also carefully watch for any side effects you might experience. The exact number and frequency of visits will be explained by the study team. They will also tell you the total length of time you will be involved in the study.